GENET archive

[Index][Thread]

BUSINESS & POLICY: BIO unveils strategic initiative to speed scientific breakthroughs, develop cures and grow the bio-economy



                                  PART 1


------------------------------- GENET-news -------------------------------

TITLE:   BIO UNVEILS STRATEGIC INITIATIVE TO SPEED SCIENTIFIC BREAKTHROUGHS, DEVELOP CURES AND GROW THE BIO-ECONOMY

SOURCE:  Biotechnology Industry Organisation, USA (BIO)

AUTHOR:  Press Release

URL:     http://www.bio.org/news/pressreleases/newsitem.asp?id=2011_0629_04

DATE:    29.06.2011

SUMMARY: "?Mankind?s need for the promise of biotechnology to cure disease, to combat hunger, and to discover new forms of energy has never been more urgent,? said Jim Greenwood, BIO?s President and CEO. ?Yet despite the extraordinary hope offered by biotechnology, government policies and the capital formation environment necessary to support these policies are insufficiently conducive to enable our industry to most effectively meet these challenges. Our policy proposals are designed to improve the odds for biotech innovation and the patients and communities we serve.?"

----- archive: http://www.genet-info.org/information-services.html -----


BIO UNVEILS STRATEGIC INITIATIVE TO SPEED SCIENTIFIC BREAKTHROUGHS, DEVELOP CURES AND GROW THE BIO-ECONOMY

?Unleashing the Promise of Biotechnology: Advancing American Innovation to Cure Disease and Save Lives? Provides Roadmap for Transformative Policy Changes

WASHINGTON, D.C. (Wednesday, June 29, 2011) - The Biotechnology Industry Organization (BIO) released today a summary of legislative proposals to reform the investment and regulatory environment for biotech innovation. These proposals are designed to unleash the innovation required to cure disease and make the U.S. healthcare system more affordable, efficient, and of higher quality, as well as to foster the development of breakthrough technologies to provide alternative energy sources, combat hunger and protect against bio-terrorism. The policy proposals, released at a press briefing at the 2011 BIO International Convention held here this week, will serve as the organization?s targeted advocacy plan in these two areas.

?Mankind?s need for the promise of biotechnology to cure disease, to combat hunger, and to discover new forms of energy has never been more urgent,? said Jim Greenwood, BIO?s President and CEO. ?Yet despite the extraordinary hope offered by biotechnology, government policies and the capital formation environment necessary to support these policies are insufficiently conducive to enable our industry to most effectively meet these challenges. Our policy proposals are designed to improve the odds for biotech innovation and the patients and communities we serve.?

BIO?s comprehensive set of policy proposals address two vital needs for ensuring robust biotechnology innovation and industry growth: 1) the need to re-engineer the biotech economic model, and 2) the need to re-invent the idea-to-market pathway for biotech cures and other products. BIO plans to pursue these proposals by advocating for legislation, specifically by turning the relevant findings in to language that will be used to advocate for introduction and passage of legislation.

?BIO has consistently succeeded in contributing to the development of important and effective policy at the federal, state and international levels,? said Greenwood. ?Our efforts notwithstanding, the legal and regulatory structures in place remain woefully insufficient to incentivize the magnitude of investment necessary in the biotechnology sector to translate the scientific potential that resides in the thousands of small, medium and large American biotech companies into products that save lives and fuel and feed the world in environmentally sustainable ways.?

To that end, BIO interviewed thought leaders within and outside of the industry for the purpose of developing game-changing strategies to bolster biotech innovation.BIO enlisted the support of Dr. Elias Zerhouni, the former Director of the National Institutes of Health, to conduct an analysis of industry challenges and a more comprehensive survey of medical experts, academic researchers, and other life science leaders to suggest out-of-the-box, big ideas to significantly advance biotechnology?s chances to succeed for patients and consumers.

Members of BIO?s Board of Directors and staff then worked to review these ideas, debate their merits, and consider additional approaches to develop a targeted national policy strategy to address these two key challenges.Additionally, BIO sought, and will continue to seek, input from Members of Congress, federal agencies and institutes, patient organizations, former high-level government employees, former Members of Congress, and other policy experts.

?Only by transforming the policy environment can we create a robust 21st century innovation economy, maintain our biotechnology global leadership, produce hundreds of thousands of high-paying jobs in the United States, and prevent the tsunami of additional health care costs that will be associated with the aging baby-boomer population,? said Greenwood.

The BIO International Convention wraps up tomorrow in Washington, D.C. The Convention is the largest global event for the biotechnology industry, offering networking and partnering opportunities with policymakers, scientists, CEOs and newsmakers, and hundreds of sessions covering biotech trends, policy issues and technological innovations. For more information, visit http://convention.bio.org.



                                  PART 2

------------------------------- GENET-news -------------------------------

TITLE:   NATIONAL SURVEY SHOWS AMERICAN VOTERS AND BIOTECH INDUSTRY ALIGNED ON KEY POLICY PRIORITIES - CURING DISEASE AND IMPROVING LIVES

SOURCE:  Biotechnology Industry Organisation, USA (BIO)

AUTHOR:  Press Release

URL:     http://www.bio.org/news/pressreleases/newsitem.asp?id=2011_0630_02

DATE:    30.06.2011

SUMMARY: "A new national survey of 800 American voters by the Biotechnology Industry Organization - and conducted by the bipartisan pairing of Public Opinion Strategies and Hart Research Associates - has found that during the current economic slowdown, while the nation?s leaders are making hard choices about our national economic policies, a majority (53%) of voters believe the federal government should support the biotechnology industry through either tax policies or direct funding."

----- archive: http://www.genet-info.org/information-services.html -----


NATIONAL SURVEY SHOWS AMERICAN VOTERS AND BIOTECH INDUSTRY ALIGNED ON KEY POLICY PRIORITIES - CURING DISEASE AND IMPROVING LIVES

WASHINGTON, D.C. (Thursday, June 30, 2011) - A new national survey of 800 American voters by the Biotechnology Industry Organization - and conducted by the bipartisan pairing of Public Opinion Strategies and Hart Research Associates - has found that during the current economic slowdown, while the nation?s leaders are making hard choices about our national economic policies, a majority (53%) of voters believe the federal government should support the biotechnology industry through either tax policies or direct funding.

?These numbers are a testament to the life-saving scientific research being conducted by biotechnology industry. Every day biotech researchers are working to cure deadly diseases, find cleaner alternative fuels, protect us against the threats of bioterrorism and feed a hungry world. It is reassuring to know that our hard work lines up shoulder-to-shoulder with the priorities of the American people,? said Jim Greenwood, CEO of the Biotechnology Industry Organization.

The survey, conducted between June 5 and 7, found that American voters embrace a continued federal commitment to biotechnology priorities such as research dedicated to finding alternative sources of energy, life-saving medicines and cures. In fact, the survey found that the key biotechnology industry issues are ranked by voters as either ?extremely? or ?very? important - behind only the economy, education, reducing the deficit/government spending - and alongside of issues such as combating terrorism and reducing taxes.

Over three-quarters of voters (76%) are supportive of a continued commitment to federal spending on biotech research after hearing that the industry is working to cure diseases such as Alzheimer?s, cancer, diabetes and Parkinson?s - and that these cures will eventually help patients, cut federal spending and save the American budget trillions of dollars.

Greenwood concluded, ?These numbers reflect American faith in the promise of biotechnology. Each day, the men and women of the biotech industry are focused on developing the key breakthroughs that will allow Americans to not only live longer, but to lead better, healthier and more productive lives.?

Methodology

The national survey of N=800 registered voters was conducted June 5-7, 2011by Public Opinion Strategies and Peter D. Hart Research Associates on behalf of the Biotechnology Industry Organization.

Public Opinion Strategies (POS) and Hart Research Associates are leading national survey research companies who have been at the cutting edge of change in the field of public opinion for several decades. The firms partner on a number of bi-partisan research efforts, not least of which is the NBC News/Wall Street Journal poll ? a flagship survey that is widely regarded as a barometer of American opinion.